ERDOSTEINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C8H11NO4S2
Molecular Weight	249.307
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CSCC(=O)NC1CCSC1=O

InChI

InChIKey=QGFORSXNKQLDNO-UHFFFAOYSA-N

InChI=1S/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12)

HIDE SMILES / InChI

Molecular Formula	C8H11NO4S2
Molecular Weight	249.307
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description

Erdosteine is an antioxidant compound developed by Edmond Pharma and approved in Europe for the treatment of chronic bronchitis and COPD. Erdosteine has two thiol groups and is believed to act as a free radicals scavenger (through the formation of the active metabolite I, N-thiodiglycolylhomocysteine). Also the drug effect may be due to the inhibition of the activity of elastase enzyme and its interaction with mucosa. The drug got Orphan Drug designation by FDA for the treatment of bronchiectasis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition
mucus secretion 5	Modulator 657	Bronchitis, Chronic
Neutrophil elastase 1	Inhibitor 6467	Bronchitis, Chronic
reactive oxygen species biosynthetic process 23	Antagonist 2202	Bronchitis, Chronic

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pulmonary Disease, Chronic Obstructive 68	Primary	reactive oxygen species biosynthetic process mucus secretion Neutrophil elastase	Approved 7678	ERDOTIN
Bronchitis, Chronic 37	Primary	reactive oxygen species biosynthetic process mucus secretion Neutrophil elastase	Approved 7678	ERDOTIN

PubMed

Title	Date	PubMed
Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease.	2007 Dec	20477170
Raft of results energizes researchers.	2009 Sep-Oct	20214263
Free radical scavenging activity of erdosteine metabolite I investigated by electron paramagnetic resonance spectroscopy.	2010	20215809
Ambroxol - Resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases.	2010 Apr	20616932
Effectiveness of erdosteine, a second generation mucolytic agent, in children with acute rhinosinusitis: a randomized, placebo controlled, double-blinded clinical study.	2010 Apr	20055782
Beneficial effect of erdosteine on methotrexate-induced testicular toxicity in mice.	2010 Aug	20504824
Effects of sulphurous water on human neutrophil elastase release.	2010 Dec	20650977
Association between lung function and exacerbation frequency in patients with COPD.	2010 Dec 9	21191438
Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis.	2010 Feb 8	20137099
Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: effect of exenatide.	2010 Jul-Sep	20616412
Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study.	2010 Jun	20334478

Patents

Sample Use Guides

In Vivo Use Guide

1 capsule (300 mg) 2-3 times a day

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Tue Mar 06 12:14:51 UTC 2018` Edited by `admin` on `Tue Mar 06 12:14:51 UTC 2018`
Record UNII	76J0853EKA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ERDOSTEINE

Official Name

English

ERDOSTEINE [MART.]

Common Name

English

ERDOSTEINE [INN]

Common Name

English

ERDOSTEINE [MI]

Common Name

English

(+/-)-((((TETRAHYDRO-2-OXO-3-THIENYL)CARBAMOYL)METHYL)THIO)ACETIC ACID

Systematic Name

English

MUCOTEC

Brand Name

English

ERDOSTEINE [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

R05CB15